Scarica l'app Stockscreener
7.13
3.39%
-0.25
Dopo l'orario di chiusura:
7.34
0.21
+2.95%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NEO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.38
Aprire:
$7.35
Volume 24 ore:
1.95M
Relative Volume:
0.96
Capitalizzazione di mercato:
$917.63M
Reddito:
$628.25M
Utile/perdita netta:
$-78.55M
Rapporto P/E:
-11.50
EPS:
-0.62
Flusso di cassa netto:
$-29.73M
1 W Prestazione:
-3.26%
1M Prestazione:
-9.06%
6M Prestazione:
-58.52%
1 anno Prestazione:
-46.99%
Intervallo 1D:
$7.11
$7.38
Intervallo di 1 settimana:
$7.02
$7.715
Portata 52W:
$6.08
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Nome
Neogenomics Inc
Settore
Industria
Telefono
(239) 768-0600
Indirizzo
9490 NEOGENOMICS WAY, FORT MYERS, FL
Confronta NEO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
7.13 | 948.48M | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
398.36 | 152.41B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
192.15 | 136.31B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
522.21 | 41.46B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.94 | 32.18B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
147.37 | 24.40B | 15.50B | 1.33B | 2.16B | 7.34 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-15 | Iniziato | Guggenheim | Neutral |
| 2025-04-30 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Iniziato | Jefferies | Buy |
| 2024-05-01 | Ripresa | Craig Hallum | Buy |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-08-21 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-02-24 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Aggiornamento | Needham | Hold → Buy |
| 2022-08-26 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Downgrade | Needham | Buy → Hold |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-03-29 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-29 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Ripresa | Stephens | Overweight |
| 2021-12-16 | Iniziato | Cowen | Outperform |
| 2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-02-25 | Ripresa | Needham | Buy |
| 2021-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-12-11 | Ripresa | BTIG Research | Buy |
| 2020-10-28 | Reiterato | Needham | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-28 | Iniziato | Guggenheim | Buy |
| 2020-07-29 | Reiterato | Needham | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Buy |
| 2020-04-21 | Ripresa | Stephens | Overweight |
| 2020-03-02 | Ripresa | Craig Hallum | Buy |
| 2020-02-28 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Reiterato | Needham | Buy |
| 2019-05-01 | Reiterato | Needham | Buy |
| 2019-03-29 | Reiterato | Needham | Buy |
| 2019-01-03 | Iniziato | Needham | Buy |
| 2018-10-24 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Iniziato | Leerink Partners | Outperform |
| 2018-05-02 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2017-08-24 | Iniziato | Gabelli & Co | Buy |
| 2016-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Neogenomics Inc Borsa (NEO) Ultime notizie
Investor Calendar Invites You to the NeoGenomics Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Tuesday March 1, 2016 - ACCESS Newswire
NeoGenomics at William Blair Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
NeoGenomics at William Blair Conference: Strategic Growth and Innovation - Investing.com Australia
Where are the Opportunities in (NEO) - news.stocktradersdaily.com
Cancer Tumor Profiling Market Rises with Demand - openPR.com
Liquid Biopsy Market for Cancer Detection, cfDNA & CTC Analysis | - openPR.com
Fort Myers-based NeoGenomics to unveil new cancer diagnostics at ASCO 2025 - Gulfshore Business
NeoGenomics unveils new oncology diagnostics at ASCO 2025 By Investing.com - Investing.com South Africa
Neogenomics director Kelly buys $38,000 in common stock - Investing.com Australia
Neogenomics director Kelly buys $38,000 in common stock By Investing.com - Investing.com Nigeria
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025 - BioSpace
NeoGenomics unveils new oncology diagnostics at ASCO 2025 - Investing.com
Health Care Stocks Rise As Pfizer And AstraZeneca Lead Gains - Finimize
NeoGenomics Approves Key Proposals at Annual Meeting - TipRanks
D. E. Shaw & Co. Inc. Trims Stock Position in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
BNP Paribas Financial Markets Sells 35,979 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Rating of “Hold” from Analysts - Defense World
NeoGenomics introduces c-MET companion diagnostic for NSCLC - Yahoo Finance
Take Care Before Jumping Onto NeoGenomics, Inc. (NASDAQ:NEO) Even Though It's 25% Cheaper - simplywall.st
NeoGenomics launches rapid c-MET diagnostic test for NSCLC - Investing.com Australia
NeoGenomics launches rapid c-MET diagnostic test for NSCLC By Investing.com - Investing.com South Africa
NeoGenomics drops as sequential revenue decline leads to Q1 miss - MSN
Neogenomics Launches C-Met Cdx Assay To Guide Treatment Decisions For Advanced Non-Small Cell Lung Cancer - marketscreener.com
NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer - Business Wire
Ameriprise Financial Inc. Reduces Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
Envista, NeoGenomics, Acadia Healthcare, Astrana Health, and Hims & Hers Health Stocks Trade Down, What You Need To Know - Yahoo Finance
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market - openPR.com
NeoGenomics to Participate in Upcoming June Investor Conferences - Bluefield Daily Telegraph
Leading Oncology Testing Firm NeoGenomics Announces Key June Investor Conference Schedule - Stock Titan
3 Healthcare Stocks with Mounting Challenges - FinancialContent
Guggenheim Begins Coverage on NeoGenomics (NASDAQ:NEO) - Defense World
NeoGenomics To Present At 39th Annual William Blair Growth Stock Conference - ACCESS Newswire
NeoGenomics opposes US PTAB discretionary denial, citing public health concerns - MLex
Guggenheim Begins Coverage of NeoGenomics (NEO) with Neutral Stance | NEO Stock News - GuruFocus
Guggenheim Initiates Coverage on NeoGenomics With Neutral Rating - marketscreener.com
NeoGenomics (NEO) Initiated with Neutral Rating by Guggenheim Analyst | NEO Stock News - GuruFocus
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Tower Research Capital LLC TRC - Defense World
NEO Q1 Earnings Call: Sales Growth, Pharma Headwinds, and Pathline Integration Shape Outlook - Yahoo Finance
NeoGenomics (NASDAQ:NEO) Upgraded to Hold at StockNews.com - Defense World
Insider Buying: Stephen Kanovsky Acquires Shares of NeoGenomics Inc (NEO) - GuruFocus
Chief Financial Officer of NeoGenomics Jeffrey Sherman Buys 14% More Shares - Yahoo Finance
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in oncology using the UG 100 sequencing platform - SelectScience
NeoGenomics, Inc. to Host Earnings Call - ACCESS Newswire
Insider Buying: Neil Gunn Acquires Shares of NeoGenomics Inc (NE - GuruFocus
Assessing NeoGenomics: Insights From 9 Financial Analysts - Benzinga
Piper Sandler Lowers Price Target on NeoGenomics (NEO) to $12.00 - GuruFocus
Piper Sandler Lowers Price Target on NeoGenomics (NEO) to $12.00 | NEO Stock News - GuruFocus
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays - Investing.com
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays - MarketBeat
NeoGenomics (NEO) Receives Adjusted Price Target from Piper Sand - GuruFocus
NeoGenomics (NEO) Receives Adjusted Price Target from Piper Sandler | NEO Stock News - GuruFocus
Neogenomics Inc Azioni (NEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):